文献速递头颈外科

HPV阳性口咽癌原发手术后包膜外侵犯、病理淋巴结状态与辅助治疗:全国医院回顾性队列分析

Extracapsular extension, pathologic node status, and adjuvant treatment in primary surgery patients with human papillomavirus-mediated oropharyngeal cancer: National hospital-based retrospective cohort analysis.
PubMed 文献 · Head Neck · 2021-07-31

该全国医院回顾性队列纳入2663例接受原发手术的pN+ HPV+口咽癌患者,评估包膜外侵犯(ECE)与辅助治疗模式对生存的影响。结果显示ECE阳性者死亡风险为ECE阴性者的1.74倍(95%CI 1.26-2.40,p=0.001);在pN1 ECE阳性、pN2 ECE阳性及晚期ECE阳性(如pT3-T4pN2)患者中,辅助放疗或放化疗未较单纯手术或辅助放疗显著降低死亡风险。结论支持扩大ECE阳性患者术后降强度临床试验的入组标准。

要点

  • ECE阳性使HPV+口咽癌术后pN+患者死亡风险增加1.74倍(95%CI 1.26-2.40)。
  • pN1 ECE阳性者辅助放疗或放化疗未显著改善总生存。
  • pN2 ECE阳性者辅助放疗与放化疗的总生存风险相似。

核心结论

  • 病理ECE阴性预测HPV+口咽癌术后pN+患者生存更差。
  • 分析支持扩大ECE阳性患者术后降强度临床试验的入组标准。

研究设计与样本

  • 全国医院回顾性队列研究,纳入2663例接受原发手术的pN+ HPV+口咽癌患者。

主要发现

  • ECE阳性患者死亡风险为ECE阴性者的1.74倍(95%CI 1.26-2.40,p=0.001)。
  • pN1 ECE阳性者中,辅助放疗(aHR 0.81,95%CI 0.36-1.85,p=0.62)或辅助放化疗(aHR 0.66,95%CI 0.34-1.32,p=0.24)与单纯手术的总死亡风险相似。
  • pN2 ECE阳性者中,辅助放疗与辅助放化疗的总死亡风险相似(HR 1.04,95%CI 0.24-4.47,p=0.96)。
  • 晚期ECE阳性(如pT3-T4pN2)患者中,辅助放化疗未较辅助放疗降低总死亡风险。

临床怎么用

  • ECE阳性HPV+口咽癌术后pN+患者可考虑纳入术后降强度临床试验。
  • pN1 ECE阳性者辅助治疗选择需权衡,单纯手术可能已足够。
  • pN2 ECE阳性者辅助放疗可作为放化疗的替代选项。
  • 晚期ECE阳性者辅助放化疗未显示优于辅助放疗。

局限性

  • 回顾性队列设计可能存在选择偏倚和混杂。
  • 原文未报告各治疗组的具体样本量。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The significance of extracapsular extension (ECE) and adjuvant treatment paradigm in patients with surgically managed human papillomavirus-positive (HPV+) oropharyngeal cancer (OPC) is debated. METHODS: National, hospital-based, retrospective cohort study of 2663 patients pN+ HPV+ OPC who underwent primary surgery. RESULTS: Patients with ECE had a 1.74-times risk of death (95% confidence interval [CI]: 1.26-2.40, p = 0.001) compared to patients without ECE. Among patients with pN1, ECE-positive disease, risk of overall mortality was similar across treatment paradigms (surgery alone: ref; adjuvant radiation therapy [RT]: aHR: 0.81; 95% CI: 0.36-1.85; p = 0.62; adjuvant CRT: aHR: 0.66; 95% CI: 0.34-1.32; p = 0.24). Patients with pN2 ECE-positive disease treated with adjuvant RT alone exhibited similar risk of all-cause mortality (hazard ratio: 1.04, 95% CI: 0.24-4.47, p = 0.96) compared to adjuvant chemoradiation (CRT). In patients with advanced, ECE-positive disease (e.g., pT3-T4pN2), adjuvant CRT did not reduce the risk of overall mortality relative to adjuvant RT. CONCLUSION: Although pathologic ECE negatively predicts for survival in patients with HPV+ OPC, our analyses support expansion of postoperative de-intensification clinical trial eligibility criteria in patients with ECE-positive disease.

来源:Head Neck,查看原文。版权归原作者所有。

引用

  1. Day AT, Yang AM, Tanamal P, et al. Extracapsular extension, pathologic node status, and adjuvant treatment in primary surgery patients with human papillomavirus-mediated oropharyngeal cancer: National hospital-based retrospective cohort analysis. Head Neck. 2021. PMID: 34331477. doi:10.1002/hed.26825

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。